# 2/3 COMpAAAS Tripartite: ART-CC, KP, and VA

> **NIH NIH U01** · KAISER FOUNDATION RESEARCH INSTITUTE · 2020 · $610,414

## Abstract

PROJECT SUMMARY/ABSTRACT
HIV+ adults who drink are already physiologically frail due to HIV infection, comorbidity (including hepatitis C
infection), polypharmacy and associated substance use. In this setting, biomedical consequences of alcohol
use can occur with moderate use and are often unappreciated or misattributed. The “Consortium to improve
OutcoMes in HIV/Aids, Alcohol, Aging & multi-Substance” (COMpAAAS) is supported by NIH/NIAAA award
U24AA020794 to study this issue in a single sample, the Veterans Aging Cohort Study (VACS) (~50,000 HIV+
US veterans demographically matched to ~100,000 uninfected comparators). VACS will employ a direct
alcohol biomarker (Phosphatidyl-ethanol [PEth] and a validated measure of physiologic frailty (VACS Index). In
this set of three applications, the Antiretroviral Therapy Cohort Collaboration (ART-CC) and Kaiser
Permanente (KP) teams join the Veterans Healthcare System (VA) team as COMpAAAS Tripartite: ART-CC,
KP, and VA. Our long term goal is to inform alcohol intervention design and implementation. Together we
propose to study biomedical consequences of alcohol and associated substance use in HIV, extending the
scope and generalizability of VACS to multiple healthcare systems in North America and Europe and
substantially increasing sample size and diversity of HIV+ subjects. Importantly, COMpAAAS Tripartite also
expands the sample of uninfected comparators, a critically important group if we are to understand how alcohol
differentially affects biomedical outcomes in HIV. KP will be able to identify demographically-matched
uninfected comparators from their Northern California region. A new VA sample of veterans born in 1945-1965
(Birth Cohort) expands access to Hepatitis C infected (HCV+) and women comparators. The tripartite group
will also participate in an HIV+ substudy (n=2250), The Medications, Alcohol, Substance Use in HIV Study
(MASH), in which new data on potentially inappropriate medications (PIMS) and biomarkers for alcohol and
substances (tobacco, marijuana, opioids, cocaine, and methamphetamine) will be collected. As the lead site
for Aim 2, KP will examine the impact of alcohol and smoking on HIV outcomes, preventive care, and medical
comorbidities. We anticipate that among HIV+ individuals, hazardous alcohol use, alcohol use disorders and
smoking will negatively impact each of these outcomes; and that these effects will be amplified in HIV+
individuals compared with uninfected individuals. Initially, analyses will use electronic health record data
including self-reported alcohol and substance use. Analyses will be repeated in the final year correcting for
biases in self-reported alcohol and substance use based upon MASH results. Consistent with the RFA, all
grants contribute data for all aims, have identical aims and protocols. This application addresses key
interactions between alcohol and tobacco use, antiretrovirals, and medications that may increase mortality,
hospitalization, frailty, an...

## Key facts

- **NIH application ID:** 10007744
- **Project number:** 5U01AA026230-04
- **Recipient organization:** KAISER FOUNDATION RESEARCH INSTITUTE
- **Principal Investigator:** Derek D Satre
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $610,414
- **Award type:** 5
- **Project period:** 2017-09-15 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10007744

## Citation

> US National Institutes of Health, RePORTER application 10007744, 2/3 COMpAAAS Tripartite: ART-CC, KP, and VA (5U01AA026230-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10007744. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*